• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Study shows prostate MRI quality varies greatly across global sites

News
Article

Researchers utilized the PI-QUAL scoring system to assess 355 mpMRI exams performed at 41 facilities in 18 countries.

A multinational study published in Radiology showed that there is a significant amount of variability among international locations in the quality of imaging for prostate multiparametric magnetic resonance imaging (mpMRI) exams.1

“ … Thus, the clinical implications of the study are that centers with diagnostic or treatment services for prostate cancer should take part in quality improvement projects with the aid of quality evaluation systems such as PI-QUAL to optimize their MRI quality and produce clinically useful images for their patients,” wrote lead study author Francesco Giganti, MD, PhD, and colleagues.

“ … Thus, the clinical implications of the study are that centers with diagnostic or treatment services for prostate cancer should take part in quality improvement projects with the aid of quality evaluation systems such as PI-QUAL to optimize their MRI quality and produce clinically useful images for their patients,” wrote lead study author Francesco Giganti, MD, PhD, and colleagues.

For the study, researchers utilized the PI-QUAL scoring system to assess 355 mpMRI exams performed at 41 facilities in 18 countries from September 2021 to August 2022.

Out of a total of 71 MRI scanners, the researchers found that only 23 scanners (32%) achieved a PI-QUAL score of 5 for optimal imaging quality. According to the study, 39 scanners (55%) had a PI-QUAL score of 4 for sufficient image quality and 9 scanners (13%) had a PI-QUAL score of 3 for sufficient MRI quality.

For the 48 scanners that did not have optimal PI-QUAL scores, the researchers pointed out that dynamic contrast-enhanced (DCE) sequences demonstrated the least adherence to version 2.1 of the Prostate Imaging Reporting and Data System (PI-RADS 2.1). This was evident for 44 of the 48 scanners (92%), according to the study authors. The researchers also noted questionable PI-RADS 2.1 adherence in diffusion-weighted imaging (DWI) for 20 scanners (42 %) and T2-weighted imaging for 19 scanners (40 %).

“Good image quality has been shown to improve the ability to detect prostate cancer, the accuracy of staging decisions, upstaging after radical prostatectomy, and decision-making for nerve sparing during radical prostatectomy,” wrote lead study author Francesco Giganti, MD, PhD, who is affiliated with the Departments of Radiology and Urology at the University College London Hospital NHS Foundation Trust in London, and colleagues.

“ … Thus, the clinical implications of the study are that centers with diagnostic or treatment services for prostate cancer should take part in quality improvement projects with the aid of quality evaluation systems such as PI-QUAL to optimize their MRI quality and produce clinically useful images for their patients.”

In the second phase of the study, researchers provided feedback to centers that did not achieve optimal PI-QUAL scoring. The most common recommendations for improvement for prostate MRI imaging were as follows:

• adjusting temporal resolution to a maximum of 15 seconds for DCE imaging (56%);

• inclusion of an acquired/calculated high b value of greater than 1400 sec/mm2 for DWI sequences (40%)

• utilizing fat suppression sequences for DCE imaging (33%); and

• adjusting in-plane resolution as per PI-RADS 2.1 guidelines for T2-weighted imaging (21%).

“After centers received feedback and modified their MRI sequences, we observed a clear improvement in the overall quality of scans across the majority of centers in the study with 97% of the scans at the end of phase II reaching a PI-QUAL score of 5,” added Giganti and colleagues.

In regard to study limitations, the researchers suggested that clinicians from those centers that participated in the study may have had a more academic approach to imaging, which may have led to a baseline MRI quality beyond what one may see in routine clinical practice. Noting that the PI-QUAL scoring system used in the study is limited to assessment of mpMRI, Giganti and colleagues suggested that modifications to PI-QUAL would be necessary in order to apply to biparametric MRI if that emerges as a standard of care.

Reference

1. Giganti F, Ng A, Asif A, et al. Global Variation in Magnetic Resonance Imaging Quality of the Prostatez.Radiology. 2023;309(1):e231130. doi: 10.1148/radiol.231130

Related Videos
David I. Lee, MD, FACS, answers a question during a video interview
Todd M. Morgan, MD, answers a question during a Zoom video interview
Man talking with doctor | Image Credit: © rocketclips - stock.adobe.com
Prostate cancer cell division | Image Credit: © PRB ARTS - stock.adobe.com
Group of doctors reading a document | Image Credit: © Flamingo Images - stock.adobe.com
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.